Skip to main content
. 2018 Jul 5;103(10):1720–1729. doi: 10.3324/haematol.2017.187385

Figure 7.

Figure 7.

iCD16+NK-92 +/− 7G3 or isotype control treatment of primary acute myeloid leukemia (AML) xenografted mice. NOD/SCID gammanull (NSG) mice were inoculated intravenously (i.v.) with 3×106 passage human AML spleen-derived cells (day 0) and treated with iCD16+NK-92 +/− 7G3 or BM4 × 5 doses [intraperitoneal injection (i.p.)] (3×/week) starting on day 3 (A). Controls included no therapy and antibodies alone (n=5 for all groups). Survival was determined using Kaplan-Meier survival analysis with a log rank test (B).